GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guizhou Sanli Pharmaceutical Co 603439.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

10.97

+1.20%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.70bn

FY2016FY2025

Net income

CN¥46.3m

FY2016FY2025

Free cash flow

CN¥138.7m

FY2016FY2025

Shareholders' equity

CN¥1.45bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.70bnCN¥2.14bnCN¥1.63bnCN¥1.20bnCN¥939.0mCN¥630.2mCN¥883.8mCN¥722.3mCN¥638.3mCN¥514.6m
Gross profitCN¥1.19bnCN¥1.49bnCN¥1.20bnCN¥861.8mCN¥661.9mCN¥421.2mCN¥585.0mCN¥472.6mCN¥424.3mCN¥334.7m
Research and developmentCN¥27.9mCN¥46.5mCN¥30.6mCN¥17.9mCN¥7.7mCN¥5.6mCN¥3.5mCN¥6.9mCN¥2.7mCN¥5.6m
Operating incomeCN¥75.0mCN¥326.2mCN¥335.8mCN¥225.5mCN¥179.2mCN¥112.3mCN¥154.6mCN¥99.8mCN¥87.5mCN¥66.6m
Net incomeCN¥46.3mCN¥274.0mCN¥292.7mCN¥201.3mCN¥152.3mCN¥94.0mCN¥133.1mCN¥110.5mCN¥87.6mCN¥74.9m
Diluted earnings per share0.120.690.670.500.380.270.340.300.230.21

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥2.85bnCN¥3.19bnCN¥2.92bnCN¥1.82bnCN¥1.40bnCN¥1.26bnCN¥730.8mCN¥576.7mCN¥565.4mCN¥518.0m
Cash and short-term investments—CN¥497.8mCN¥622.9mCN¥630.8mCN¥642.2mCN¥450.1mCN¥239.6mCN¥131.4mCN¥180.5mCN¥177.3m
Total liabilitiesCN¥1.34bnCN¥1.60bnCN¥1.21bnCN¥578.4mCN¥372.9mCN¥276.9mCN¥79.7mCN¥58.7mCN¥92.1mCN¥87.4m
DebtCN¥149.7mCN¥561.0mCN¥610.0mCN¥205.7mCN¥200.0mCN¥200.0m————
Shareholders' equityCN¥1.45bnCN¥1.53bnCN¥1.47bnCN¥1.24bnCN¥1.03bnCN¥981.9mCN¥651.1mCN¥518.0mCN¥473.4mCN¥430.6m
Shares outstanding381m397m434m399m403m350m393m365m378m360m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥164.6mCN¥107.1mCN¥276.7mCN¥293.3mCN¥155.0mCN¥63.2mCN¥116.2mCN¥75.3mCN¥57.5mCN¥35.1m
Capital spending−CN¥25.8m−CN¥45.2m−CN¥108.7m−CN¥119.9m−CN¥26.1m−CN¥51.7m−CN¥8.0m−CN¥1.8m−CN¥7.2m−CN¥12.4m
Free cash flowCN¥138.7mCN¥61.9mCN¥168.0mCN¥173.4mCN¥129.0mCN¥11.5mCN¥108.2mCN¥73.6mCN¥50.3mCN¥22.7m
Dividends paid−CN¥161.4m−CN¥104.0m−CN¥41.0m−CN¥8.9m−CN¥101.8m−CN¥2.6m−CN¥110.2m−CN¥70.4m−CN¥44.9m−CN¥64.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥177.6mCN¥381.7mCN¥664.3mCN¥336.7mCN¥293.2mCN¥408.6mCN¥697.3mCN¥526.9m
Gross profitCN¥124.5mCN¥274.0mCN¥478.4mCN¥240.8mCN¥203.9mCN¥268.2mCN¥488.9mCN¥374.4m
Operating income−CN¥9.2mCN¥61.2mCN¥111.7m−CN¥1.2mCN¥42.2mCN¥49.7mCN¥91.9mCN¥96.7m
Net income−CN¥7.2mCN¥44.4m−CN¥34.5m−CN¥2.3mCN¥41.1mCN¥41.9mCN¥79.9mCN¥77.1m
Diluted earnings per share-0.020.12-0.09-0.010.110.110.200.19
Cash from operations———CN¥33.0mCN¥32.0m−CN¥14.0m—CN¥66.0m
Capital spending−CN¥14.0m−CN¥5.0m−CN¥2.0m−CN¥7.0m−CN¥11.0m−CN¥5.0m−CN¥7.0m−CN¥14.0m
Free cash flow———CN¥26.0mCN¥21.0m−CN¥19.0m—CN¥52.0m
Total assetsCN¥2.57bnCN¥2.81bnCN¥2.85bnCN¥2.85bnCN¥2.93bnCN¥3.14bnCN¥3.19bnCN¥3.06bn
Cash and short-term investments———CN¥325.4mCN¥303.0mCN¥419.2mCN¥497.8mCN¥593.1m
DebtCN¥149.6mCN¥149.5mCN¥149.7mCN¥628.2mCN¥722.3mCN¥695.9mCN¥560.8mCN¥532.0m
Shareholders' equityCN¥1.47bnCN¥1.49bnCN¥1.45bnCN¥1.48bnCN¥1.48bnCN¥1.57bnCN¥1.53bnCN¥1.60bn

Financial ratios

Data as of 18 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin70.0%69.5%73.2%71.7%70.5%66.8%
Operating margin4.6%15.8%20.7%19.0%19.7%17.8%
Net margin2.7%12.8%17.9%16.8%16.2%14.9%
Return on equity3.2%17.9%19.9%16.2%14.8%9.6%
Return on assets1.6%8.6%10.0%11.1%10.8%7.5%
Free cash flow yield4.4%3.4%7.9%9.2%4.0%2.9%
Revenue growth-20.6%31.2%36.1%27.9%49.0%-28.7%
Earnings growth-83.1%-6.4%45.4%32.2%62.1%-29.4%
Current ratio1.47x1.46x1.78x2.14x3.05x3.49x
Debt to equity0.10x0.37x0.38x0.17x0.19x0.20x
Equity ratio50.8%47.8%50.3%68.2%73.4%78.0%
Interest coverage7.12x23.19x81.21x42.98x22.12x50.22x
R&D as a share of sales1.6%2.2%1.9%1.5%0.8%0.9%
Buybacks as a share of market value3.9%8.5%-8.6%0.8%-15.2%11.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.3%22.0%16.8%
Operating income-30.7%-7.8%3.9%
Net income-38.7%-13.2%-1.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin69.7%70.9%70.6%69.2%
Operating margin10.4%14.4%15.2%15.1%
Net margin8.3%12.2%12.9%13.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings96.418.828.027.241.775.4
Price to sales2.62.45.04.66.811.2

Dividends and splits

Per share, in the currency the company pays

Paid for 3 years. Last went ex-dividend on 30 Jun 2026.

FY2026FY2025FY2024FY2023FY2021
Paid in the year0.060.340.200.100.25

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.